A Two Year Safety and Efficacy Study in Obese Patients (0364-015)(TERMINATED)
A 2-Year Study to Assess the Efficacy, Safety, and Tolerability of Taranabant in Obese Patients Followed by a 1-Year Extension
Sponsor: Merck Sharp & Dohme LLC
Terminated
The overall profile does not support development for obesity
A PHASE3 clinical study on Obesity, this trial is terminated or withdrawn. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 8 data snapshots since 2005. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Present [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jun 2022 — Jul 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jun 2022 [monthly]
Terminated PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE3
First recorded
Sep 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Merck Sharp & Dohme LLC
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.